Restrictive Cardiomyopathy Genetic Test: Heart Muscle Genes and Results

Restrictive cardiomyopathy is an uncommon heart-muscle disorder in which one or both ventricles become unusually stiff and cannot fill normally, even when pumping strength appears preserved. A genetic test can help determine whether this physiology reflects an inherited myocardial disease, identify relatives who need surveillance, and sometimes reveal a diagnosis that changes management. It is not a stand-alone test for every person with shortness of breath, atrial enlargement, or heart failure. Similar findings can result from cardiac amyloidosis, iron overload, inflammatory disease, radiation injury, storage disorders, and other acquired or systemic conditions. The most useful evaluation therefore combines careful phenotyping, imaging, rhythm assessment, laboratory studies, family history, and appropriately selected DNA analysis. Results may be pathogenic or likely pathogenic, uncertain, or negative, and each category has different implications. Because restrictive cardiomyopathy overlaps genetically and clinically with hypertrophic, dilated, and skeletal-muscle cardiomyopathies, interpretation is best coordinated by a multidisciplinary inherited-cardiac-disease team.

• Restrictive physiology describes impaired ventricular filling; it does not identify the cause by itself.
• Genetic testing is most informative after detailed cardiac and systemic evaluation.
• TNNI3, MYH7, FLNC, DES, and several other genes can cause overlapping cardiomyopathy phenotypes.
• A pathogenic result can guide family testing, surveillance, and selected disease-specific care.
• A variant of uncertain significance should not be used to diagnose relatives or make irreversible decisions.
• A negative panel does not exclude inherited disease or non-genetic restrictive cardiomyopathy.

Table of Contents

• What restrictive physiology means
• Inherited disease and important phenocopies
• Heart-muscle genes and overlapping phenotypes
• Clinical evaluation and test selection
• Understanding genetic test results
• Management, prognosis, and monitoring
• Inheritance and family testing
• When testing is negative or uncertain

What restrictive physiology means

Restrictive cardiomyopathy, often abbreviated RCM, is defined by abnormal ventricular filling caused by reduced compliance of the heart muscle. The ventricles may be normal in size and may show little or no wall thickening, particularly early in disease. Because blood cannot enter them normally during diastole, pressure rises upstream. The atria commonly enlarge, pulmonary and systemic venous pressures increase, and symptoms of congestion develop. Left ventricular ejection fraction can remain normal until later stages, so a reassuring-looking pumping percentage does not rule out severe disease.

Possible symptoms include exercise intolerance, breathlessness, fatigue, abdominal swelling, leg edema, poor growth in children, palpitations, fainting, and chest discomfort. Atrial fibrillation or other atrial tachyarrhythmias may occur because the atria are stretched. Elevated filling pressures can also contribute to pulmonary hypertension, right-sided heart failure, blood-clot formation, and embolic events. Some individuals are identified before symptoms because a relative has cardiomyopathy or because an electrocardiogram or echocardiogram is abnormal.

RCM is a phenotype rather than a single molecular diagnosis. The same physiologic pattern can emerge from mutations in sarcomeric, cytoskeletal, nuclear-envelope, or intermediate-filament genes; from deposition of amyloid or iron; from inflammatory or fibrotic injury; or from systemic metabolic disease. Conversely, one disease-causing variant may produce restrictive cardiomyopathy in one relative, hypertrophic cardiomyopathy in another, and a mixed or evolving phenotype in a third. This variability is why genetic data must be interpreted alongside the person’s actual cardiac findings.

Echocardiography commonly shows biatrial enlargement, abnormal diastolic filling, and relatively nondilated ventricles. Cardiac magnetic resonance can detect scar or infiltration. Catheterization may be needed to distinguish myocardial restriction from constrictive pericarditis; genetic testing cannot make that distinction.

RCM is particularly serious in infants and children, where progression may be rapid and transplantation may be considered early. In adults, the course varies with the underlying cause, extent of myocardial damage, arrhythmia burden, pulmonary pressures, and extracardiac disease. A precise etiologic diagnosis is therefore more useful than the label “restrictive cardiomyopathy” alone.

Inherited disease and important phenocopies

A primary inherited RCM results from a genetic change that directly disrupts cardiac muscle structure or function. Clues include onset in childhood or early adulthood, multiple affected relatives, unexplained sudden death, cardiomyopathy with skeletal-muscle weakness, conduction disease, or a family pattern spanning generations. However, a negative family history is common. A variant may have arisen de novo, relatives may be too young to show disease, penetrance may be incomplete, or past diagnoses may have been missed or mislabeled.

Phenocopies are conditions that resemble inherited myocardial RCM but arise through a different mechanism. Recognizing them matters because several have targeted treatments and require specialized testing. Cardiac amyloidosis is a leading example. Transthyretin amyloidosis may be hereditary because of a TTR variant or may occur without a germline variant as wild-type ATTR. Light-chain amyloidosis is an acquired plasma-cell disorder and is not diagnosed with a cardiomyopathy gene panel. Evaluation generally includes serum and urine testing for monoclonal proteins before bone-tracer scintigraphy is interpreted. When ATTR is established, TTR sequencing distinguishes hereditary from wild-type disease and determines whether relatives need testing.

Other important mimics include hemochromatosis and other iron-overload states, sarcoidosis, Fabry disease, glycogen or lysosomal storage disorders, endomyocardial fibrosis, hypereosinophilic syndromes, systemic sclerosis, prior mediastinal radiation, and selected drug or toxic exposures. Pericardial constriction can produce nearly identical congestion and filling abnormalities even though the myocardium is not the primary problem. A broad genetic panel is not a substitute for biochemical, hematologic, inflammatory, or imaging evaluation of these causes.

The distinction is not always binary. Some metabolic and infiltrative diseases are themselves genetic. Fabry disease, for example, results from pathogenic GLA variants and may cause ventricular thickening, fibrosis, rhythm disturbance, renal disease, neuropathic pain, and other features. Hereditary transthyretin amyloidosis can present predominantly as cardiomyopathy, neuropathy, or a combination. A clinician may therefore choose a panel that includes both conventional cardiomyopathy genes and carefully selected phenocopy genes when the clinical picture justifies it.

The best genetic test is matched to the phenotype rather than chosen only because it is the largest panel available.

Heart-muscle genes and overlapping phenotypes

TNNI3, which encodes cardiac troponin I, is one of the most firmly associated genes in primary restrictive cardiomyopathy, especially in pediatric disease. Pathogenic variants alter regulation of contraction and relaxation within the sarcomere. Many are inherited in an autosomal dominant pattern, although rare recessive presentations have been described. Severe childhood cases may result from a new variant not present in either parent. The same gene can also cause hypertrophic or dilated cardiomyopathy, illustrating that a gene name does not predict a single fixed phenotype.

MYH7 is another important gene. It encodes beta-myosin heavy chain, a major sarcomeric motor protein. Pathogenic MYH7 variants are better known for hypertrophic cardiomyopathy and skeletal myopathies, but some produce restrictive physiology, mixed hypertrophic-restrictive disease, or a phenotype that changes over time. TNNT2, ACTC1, MYBPC3, and other sarcomeric genes have also been reported in individuals with restrictive or overlapping cardiomyopathy.

Genes affecting the cytoskeleton and mechanical integrity of cardiomyocytes may be relevant as well. FLNC variants can cause restrictive, dilated, hypertrophic, or arrhythmogenic cardiomyopathy and may be associated with substantial ventricular arrhythmia risk in selected families. DES encodes desmin, an intermediate-filament protein expressed in cardiac and skeletal muscle; pathogenic variants can combine cardiomyopathy with conduction block and skeletal myopathy. BAG3, LMNA, CRYAB, TTN, and MYPN may be included on clinically curated panels when the laboratory considers the gene-disease relationship and assay performance sufficiently established.

Not every gene listed on a commercial panel has equally strong evidence for restrictive cardiomyopathy. Some associations are based on a small number of families, and some genes mainly cause another cardiomyopathy that can secondarily look restrictive. Larger panels increase the chance of finding an uncertain variant without necessarily increasing the chance of a useful diagnosis. A high-quality laboratory should curate genes by evidence level, sequence regions with adequate coverage, assess clinically important deletion or duplication changes when relevant, and classify variants using accepted standards.

Because of overlap, a restrictive-cardiomyopathy test is often a curated cardiomyopathy panel rather than a short list limited to classic RCM genes. The ordering team should tell the laboratory about ventricular thickness, systolic function, fibrosis pattern, conduction abnormalities, arrhythmias, skeletal-muscle findings, age at onset, and family history. Those details can materially affect variant interpretation and help prevent an unrelated finding from being overcalled as the explanation.

Clinical evaluation and test selection

Genetic testing usually begins after a cardiologist has confirmed or strongly suspected a cardiomyopathy phenotype. The initial assessment includes a three-generation pedigree and review of heart failure, transplantation, rhythm disorders, pacemakers, sudden unexplained death, infant death, skeletal myopathy, and relevant systemic disease in relatives. Medical records and postmortem reports can be more reliable than family recollection, particularly when older relatives were told they had an “enlarged heart,” “stiff heart,” or nonspecific heart failure.

The cardiac workup commonly includes a 12-lead electrocardiogram, transthoracic echocardiogram, ambulatory rhythm monitoring, and cardiac magnetic resonance imaging. Exercise testing may assess functional capacity and provoke rhythm abnormalities when safe. Blood tests may include natriuretic peptides, troponin, blood counts, kidney and liver measures, iron studies, metabolic tests, or disease-specific biomarkers. Cardiac catheterization is sometimes used to measure pressures and distinguish restriction from constriction. Endomyocardial or extracardiac biopsy may be appropriate when infiltrative, inflammatory, or storage disease is suspected and noninvasive testing is inconclusive.

Testing the most clearly affected living relative first is usually the highest-yield strategy. If several family members are affected, the person with the earliest onset, most distinctive phenotype, or most complete records may be the best initial candidate. Testing an unaffected relative before a familial variant is known often produces an uninformative negative result: the laboratory cannot tell whether that person escaped a known family variant because none has yet been identified.

A focused panel is commonly used when the phenotype is recognizable. Exome or genome sequencing may be considered for syndromic, severe early-onset, recessive, or unresolved familial presentations. Broader testing can identify variants outside a panel but may produce more incidental and uncertain findings, and it still has technical blind spots.

Pretest counseling should define what the test can and cannot answer. Topics include possible result categories, incidental findings, insurance and privacy considerations, implications for relatives, and whether the laboratory offers family studies or periodic reanalysis. The clinician should also clarify whether phenocopy genes such as TTR or GLA are included and whether separate biochemical evaluation remains necessary. Consent for broad sequencing may include choices about medically actionable secondary findings unrelated to the cardiomyopathy.

Urgent clinical management should not be delayed while waiting for a genetic result when heart failure, dangerous arrhythmia, embolic risk, or rapidly worsening symptoms require action.

Understanding genetic test results

A pathogenic or likely pathogenic result means the laboratory found a variant with sufficient evidence to be considered disease-causing or very likely disease-causing. In a person whose phenotype fits the gene, it can establish a molecular diagnosis. The result may clarify inheritance, support testing of relatives, guide surveillance for gene-associated complications, and direct evaluation for extracardiac features. It rarely predicts the exact age of onset or severity. Two relatives with the same variant can have markedly different courses because of age, background genetics, environment, and factors that remain unknown.

The report should be read at the level of the exact variant. The gene, DNA and protein notation, transcript, classification, inheritance evidence, and laboratory interpretation all matter. A pathogenic variant in a recessive gene may indicate only carrier status if no second disease-causing variant is found. A variant in a gene with limited evidence for RCM may not explain the phenotype even if the laboratory considers the molecular change disruptive. Clinical correlation remains essential.

A variant of uncertain significance, or VUS, is not a positive diagnosis. Evidence is insufficient to determine whether the variant causes disease or is harmless. A VUS should not be used for predictive testing of healthy relatives, to exclude them from cardiac surveillance, or to justify a device, transplant, pregnancy decision, or other irreversible intervention. Family segregation studies may help the laboratory, but they should be coordinated by the genetics team rather than treated as routine “testing for the VUS.”

A negative result means no reportable disease-causing variant was identified with the test performed. It does not prove that the cardiomyopathy is non-genetic. The responsible gene may not yet be known; the variant may lie in a region the assay does not capture; a structural, mosaic, or regulatory change may have been missed; or the phenotype may have been assigned incorrectly. A negative result is particularly limited when the tested person has mild or uncertain disease or when a more clearly affected relative was available but not tested.

Laboratories may upgrade or downgrade variants as population, functional, and family evidence expands. Patients should know who will receive amended reports and how to keep contact information current.

A genetic result should end with a documented clinical plan: what diagnosis is established, what remains uncertain, whether management changes now, which relatives should be offered targeted testing or clinical screening, and when re-evaluation is appropriate. Without that translation, even a technically accurate report can be misused.

Management, prognosis, and monitoring

Management is driven primarily by physiology, symptoms, arrhythmia risk, and the underlying cause. Genetic information may refine these decisions but does not replace clinical measurements. Patients are generally followed with periodic history, examination, electrocardiography, echocardiography, rhythm monitoring, and selected cardiac magnetic resonance imaging. Frequency depends on age, severity, rate of change, gene, family history, and prior arrhythmias.

Congestion may be treated with diuretics, but dosing often requires caution because a stiff ventricle can be highly dependent on adequate filling pressure. Excessive preload reduction may cause low blood pressure, kidney dysfunction, or reduced cardiac output. Standard heart-failure drugs are individualized; evidence from common dilated cardiomyopathy cannot automatically be applied to a small, restrictive ventricle with preserved ejection fraction. Treatment of atrial fibrillation, conduction disease, and ventricular arrhythmias follows specialist assessment, and anticoagulation may be indicated when atrial arrhythmia or another thromboembolic risk is present.

Device decisions are also individualized. A pacemaker may be needed for clinically important conduction block. An implantable cardioverter-defibrillator can be appropriate after certain ventricular arrhythmias or in selected high-risk genetic and clinical settings, but a gene finding alone does not automatically mandate implantation. Scar burden, ventricular function, syncope, documented arrhythmia, family history, and the gene-variant mechanism all contribute.

Advanced heart-failure referral should occur before irreversible end-organ injury. RCM can progress despite preserved ejection fraction because filling pressure and output, not only contraction, determine severity. Pulmonary vascular resistance is especially important when transplantation is being considered. Children with severe disease may deteriorate quickly, and early coordination with a transplant center can be lifesaving. Mechanical circulatory support can be more technically challenging in small, nondilated ventricles than in classic dilated cardiomyopathy.

Etiology-specific treatment can change the trajectory. ATTR amyloidosis, AL amyloidosis, iron overload, Fabry disease, inflammatory disease, and eosinophilic disorders have distinct pathways. Identifying one of these is more actionable than applying generic RCM treatment. This is another reason not to stop at a cardiomyopathy panel when the clinical pattern suggests infiltration or systemic disease.

Pregnancy increases blood volume, heart rate, and hemodynamic demand. A person with established RCM should receive individualized preconception assessment through cardiology, maternal-fetal medicine, and genetics. Risk depends on functional status, filling pressures, pulmonary hypertension, arrhythmias, ventricular function, and prior events. The genetic result informs fetal inheritance risk but does not by itself determine whether pregnancy is medically safe.

Exercise advice should reflect phenotype and risk rather than a blanket prohibition. Shared decision-making with an inherited-cardiac-disease specialist is preferable to generic internet rules.

Inheritance and family testing

Many primary cardiomyopathy variants are inherited in an autosomal dominant pattern. A person with such a variant has a 50% chance of passing it to each child, regardless of sex. That probability is about inheritance, not outcome: a child who inherits the variant may have earlier, later, milder, or more severe disease than the parent. Age-related and incomplete penetrance mean some carriers may have normal testing for years before abnormalities emerge.

Rare forms can be autosomal recessive, meaning disease generally results when both gene copies are affected. Parents may be unaffected carriers, and siblings can have a 25% chance of being affected when both parents carry the relevant variant. X-linked, mitochondrial, and de novo mechanisms may arise in the broader differential depending on the gene and syndromic features. The laboratory report and genetic counselor should specify the mechanism supported for the exact finding rather than assuming all cardiomyopathy genes follow one rule.

When a pathogenic or likely pathogenic familial variant is known, targeted testing can identify which relatives inherited it. Relatives who test negative for that specific variant are usually released from gene-based surveillance, provided the variant fully explains the family’s disease and there is no separate clinical concern. Relatives who test positive need baseline cardiac evaluation and longitudinal monitoring even when asymptomatic. A positive predictive test shows susceptibility, not present disease.

When no causal variant has been found, first-degree relatives may still need clinical screening with electrocardiography and imaging. The interval depends on age, family history, phenotype, and professional guidance. Children require a pediatric plan rather than simply adopting an adult interval. New symptoms such as exertional breathlessness, fainting, sustained palpitations, edema, or reduced exercise capacity warrant evaluation between scheduled visits.

Testing minors is generally appropriate when childhood-onset disease is possible and surveillance can reduce risk. The process should include age-appropriate explanation and attention to the child’s future autonomy. Testing an asymptomatic child for an adult-only, non-actionable condition follows different ethical considerations, but many cardiomyopathy genes can manifest before adulthood.

Reproductive options include prenatal diagnosis and preimplantation genetic testing when a clearly established familial pathogenic variant is known. A VUS is generally not an appropriate basis, and counseling should address variable expression and residual uncertainty.

A clinic family letter can explain the diagnosis, familial variant, and recommended evaluation so relatives can seek appropriate care.

When testing is negative or uncertain

An inconclusive result should trigger reassessment rather than abandonment of the diagnosis. The team first reviews whether the phenotype is secure: Is this true myocardial restriction, constrictive pericarditis, hypertrophic cardiomyopathy with restrictive filling, an infiltrative disorder, or a mixed process? Were amyloidosis, iron overload, Fabry disease, inflammatory disease, and other relevant causes investigated with the correct non-genetic tests? Has cardiac magnetic resonance imaging or expert pathology review revealed a more specific direction?

Next steps depend on what was already tested. An updated panel with deletion-duplication analysis, exome or genome sequencing, or testing another affected relative may be reasonable when suspicion remains high. The method should address a specific limitation of the prior evaluation.

Reanalysis matters because gene-disease evidence and classifications evolve. Clinics may revisit an unresolved case after several years or sooner when new features, another affected relative, or a laboratory update emerges. Patients should retain the full report and test methodology.

A VUS may eventually be reclassified, but most uncertainty is not resolved by repeatedly checking consumer websites. Population frequency, segregation, functional studies, RNA evidence, and independent case data must be weighed systematically. Clinical care should continue on the basis of the patient’s established phenotype and family history while uncertainty remains.

Negative genetic testing does not cancel family screening when the clinical diagnosis appears inherited. Conversely, finding an uncertain variant does not convert a weak phenotype into cardiomyopathy. These two safeguards prevent opposite errors: false reassurance after a negative panel and overdiagnosis after an ambiguous result.

Urgent symptoms require medical attention regardless of test status. Fainting during exertion, sustained rapid palpitations, severe breathlessness, chest pain, new neurologic symptoms, or rapidly worsening swelling should not wait for a genetics appointment. Genetic testing is a long-term diagnostic tool; acute cardiovascular care remains guided by the person’s condition in real time.

References

1. 2023 ESC Guidelines for the management of cardiomyopathies. European Society of Cardiology guideline, 2023.
2. Advances in Cardiac Imaging and Genetic Testing for Diagnosis and Risk Stratification in Cardiomyopathies: 2024 Update. Clinical review, 2024.
3. Clinical Outcomes and Genetic Analyses of Restrictive Cardiomyopathy in Children. Cohort study, 2023.
4. MYH7 Mutations in Restrictive Cardiomyopathy. Clinical and genetic study, 2025.
5. Cardiac Amyloidosis: A Contemporary Review of Medical and Surgical Therapy. Clinical review, 2024.
6. Genetic Evaluation of Cardiomyopathy—A Heart Failure Society of America Practice Guideline. Practice guideline, 2018.

Disclaimer

This article is for general education and does not diagnose restrictive cardiomyopathy or replace individualized medical advice. Genetic results should be interpreted by qualified cardiovascular genetics professionals together with clinical findings, family history, and the laboratory’s full report. Seek urgent medical care for severe breathlessness, fainting, chest pain, sustained palpitations, or sudden neurologic symptoms.